Loading
GATA1 (Erythroid transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 1 more.
Transcriptional activator or repressor which serves as a general switch factor for erythroid development. It binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and of other genes expressed in erythroid cells. Activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2 and HMBS.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.79 (direct and indirect evidence; datatypes genetic literature 0.76, affected pathway 0.32, literature 0.96, genetic association 0.29, somatic mutation 0.94, animal model 0.71).
In plain words · GATA1 (Erythroid transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 1 more.
GATA1 (Erythroid transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 1 more.
Transcriptional activator or repressor which serves as a general switch factor for erythroid development.
No product in this corpus aims at GATA1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA GATA1: RNA tissue enriched (bone marrow 56 nTPM); blood lineage lineage enriched (granulocytes 463 nTPM); high antibody staining in 2 normal tissues. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms, Leukaemia, Skin cancer (all types)); Open Targets associates it with 3 specific cancer types at or above 0.5 (Diamond-Blackfan anemia, transient myeloproliferative syndrome, acute megakaryoblastic leukemia in down syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas GATA1 tissue; Open Targets ENSG00000102145 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Trainor C.D. et al, Nature, 1990, "Structure and evolution of a human erythroid transcription factor". Source.
Sources: HGNC HGNC:4170 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15976 (protein name, function text, keywords and locations (REST API)); CIViC gene GATA1 (2 evidence items, 0 assertions, 2 variants; diseases: Myeloid Leukaemia Associated With Down Syndrome, Transient Myeloproliferative Syndrome (GraphQL API, CC0)); Open Targets ENSG00000102145 (association with cancer (MONDO_0004992) 0.79; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.69, skin cancer 0.55, myeloproliferative neoplasm 0.73, leukaemia 0.71 (GraphQL API, CC0))
Transcriptional activator or repressor which serves as a general switch factor for erythroid development. It binds to DNA sites with the consensus sequence 5'-[AT]GATA[AG]-3' within regulatory regions of globin genes and of other genes expressed in erythroid cells. Activates the transcription of genes involved in erythroid differentiation of K562 erythroleukemia cells, including HBB, HBG1/2, ALAS2 and HMBS. Location: Nucleus (UniProt). Locus Xp11.23 (HGNC).
RNA: tissue enriched (bone marrow 56 nTPM), detected in some normal tissues. Blood: lineage enriched (granulocytes 463 nTPM).
No cancer stained high; medium in glioma, lung cancer, melanoma, prostate cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GATA1" OR ABSTRACT:"GATA1" OR TITLE:"GATA binding protein 1" OR ABSTRACT:"GATA binding protein 1" OR TITLE:"Erythroid transcription factor" OR ABSTRACT:"Erythroid transcription factor" OR TITLE:"ERYF1" OR ABSTRACT:"ERYF1" OR TITLE:"NFE1" OR ABSTRACT:"NFE1" OR TITLE:"GATA-1" OR ABSTRACT:"GATA-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GATA1, not a curated reading list.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.